Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib

Conclusion: Pretherapeutic 18F-FDG PET/CT provides prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib. A low tumor metabolism with an SUVmean of less than 4.0 before treatment predicts a longer PFS.

Source: Journal of Nuclear Medicine - May 1, 2018 Category: Nuclear Medicine Authors: Werner, R. A., Schmid, J.-S., Higuchi, T., Javadi, M. S., Rowe, S. P., Markl, B., Aulmann, C., Fassnacht, M., Kroiss, M., Reiners, C., Buck, A. K., Kreissl, M. C., Lapa, C. Tags: Clinical Source Type: research